This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about baricitinib as a potential treatment for patients with rheumatoid arthritis and reflects Lilly and Incyte's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. There is no guarantee that future study results will be consistent with study findings to-date, or that baricitinib will receive regulatory approvals or prove to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's and Incyte's filings with the United States Securities and Exchange Commission. Except as required by law, Lilly and Incyte undertake no duty to update forward-looking statements to reflect events after the date of this release.
([i]) American College of Rheumatology, Rheumatoid Arthritis, http://www.rheumatology.org/practice/cli... [http://www.rheumatology.org/practice/cli...] (Accessed: October 27, 2014)
([ii]) Hand Clinics, Advances in the Medical Treatment of Rheumatoid Arthritis, http://www.ncbi.nlm.nih.gov/pmc/articles... [http://www.ncbi.nlm.nih.gov/pmc/articles...] (Accessed: October 27, 2014)
([iii] )WHO [http://www.who.int/chp/topics/rheumatic/...] Global Burden of Disease Report, (table 7, page 32) 2004, http://www.who.int/healthinfo/global_bur... [http://www.who.int/healthinfo/global_bur...] (Accessed Nov. 11, 2014)
([iv]) Arthritis Foundation, Medications for Rheumatoid Arthritis, http://www.arthritistoday.org/about-arthritis/types-of-arthr... [http://www.arthritistoday.org/about-arthritis/types-of-arthr...] (Accessed: May 15, 2013)
Refer to: Celeste Stanley; celeste_stanley@lilly.com; +1-317-626-8896
(media)
Phil Johnson; johnson_philip_l@lilly.com; +1-317-655-6874
(investors)
Michael Booth, DPhil; mbooth@incyte.com; +1-302-498-5914
(Incyte)
Logo -- http://photos.prnewswire.com/prnh/200312... [http://photos.prnewswire.com/prnh/200312...]
Logo -- http://photos.prnewswire.com/prnh/201206... [http://photos.prnewswire.com/prnh/201206...]
